Some PDUFA's get a 3 month delay for generally minor things that might be needed (manufacturing inspection, or whatever). Typically a delay is indicative of an approval coming (better than receiving CRL and starting clock over to respond, get new date etc). SNTS had one with Uceris, others have had them and generally small dip on news of delay, followed by a good run-up. For SNTS it didn't matter as they were raising up their sales force for several months later, so it didn't hurt their plans for launching on their expectations. ACRX will have 65 reps in place for new year and in meantime are working on managed care formulary, etc with hospitals. I am not saying we see a delay for any reason, looks like they have given FDA what was required all the way through so far. I plan holding all the way either way through the decision in July or even if small hiccup. Best to all ACRX longs.
Yes, did you see the comparisons for PTX vs other companies in this space on the Needham slide deck. PTX is chaep.
I saw it up. I was trying to see if it would be crushed to $2. You picked a good one there, this is a crazy market.
You don't know how to do simple math either. 60% of 10 cents is 6 cents for you.
Look, little boy, Kitty didn't ever buy INO and didn't tell others to buy it. Others said to buy IDRA, Kitty went along for the trade. So, get this, ACRX has a big contract in EU and will likely gain approval of Zalviso soon enough in US and then later in EU. Great buy points today.
Don't waste too much on this ship of fools. They sound worried. I agree with your posts about Zalviso, also morphine has a deadly metabolite M6G which has been putting folks to sleep permanently. Less drug on board is always better, hence the high therapeutic advantage for Zalviso vs. morphine. .
I guess that was a "fake dip", fooled you so called traders leaving so much potential gain on the table. What a mess, spewing false info everyday.
Ya, they are all one rolled up sybil personality trying to make sense of it all.
Is this heading to the 200 DMA of 60 or to close the huge gap? Strange slant on chart, what if adam frickstein starts writing in again about pancreatic side effects for IBS drug (he likes to passively bash in on stocks he missed the upside in)? They run this to $120 and analyst raise targets, where are they now on low volume bleeding?
We didn't get our daily message from OO-OO. Maybe he talked with VTUS management and they said something good to him? Maybe not, not worth bashing for pennies when there are still many promising things to bash on.
Soon enough, ryan, keep the faith. Hope you bought low $4's. Best to you and the others.